Skip to main content
Evidence Snapshot

Thyroid hormone receptor alpha

CHEMBL1860 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1860
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thyroid hormone receptor alpha as ChEMBL target CHEMBL1860, mapped to UniProt P10827. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thyroid hormone receptor alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1860
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10827
Thyroid hormone receptor alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Thyroid hormone receptor alpha matters

As of 2026-09-13

Thyroid hormone receptor alpha is reviewed as Thyroid hormone receptor alpha (UniProt P10827); the current evidence base includes 8 approved drugs, 671 compounds, and 110 assays, with lead potency reaching pChEMBL 10.4.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 671 compounds, and 110 assays for this target. The dominant activity type is IC50. CHEMBL291053 is the current potency anchor at pChEMBL 10.4.

Use CHEMBL291053 as the tractability anchor when discussing potency (pChEMBL 10.4).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.4
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Thyroid hormone receptor alpha matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10827, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

671
Total Compounds
110
Total Assays
8
Approved Drugs
IC50: 426.0, KI: 113.0, EC50: 195.0, KD: 31.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL291053
 10.4 IC50 Clinical
No preferred name
CHEMBL1544
 10.2 Kd Approved
No preferred name
CHEMBL289343
 10.0 IC50 —
No preferred name
CHEMBL41314
 9.8 IC50 —
No preferred name
CHEMBL41632
 9.8 IC50 Clinical

Approved Drugs

Structure Compound First Approval
RESMETIROM
CHEMBL3261331
 2024
ROXADUSTAT
CHEMBL2338329
 2021
AMIODARONE
CHEMBL633
 1985
LEVOTHYROXINE
CHEMBL1624
 1982
LIOTHYRONINE
CHEMBL1544
 1956
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:26Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1860